Cloudflare recently announced support for aggregations in R2 SQL, a new feature that lets developers run SQL queries on data ...

Nicki Minaj made a surprise appearance at Turning Point USA’s AmericaFest on Sunday in Phoenix alongside Erika Kirk, the widow of TPUSA founder Charlie Kirk and the organization’s CEO. The pair ...

Notre Dame values its independence more than it cares about college football’s postseason. Potential for CFP bracket expansion is another reason for Notre Dame to not join a conference. Irish ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

WASHINGTON—Syria has joined the U.S.-led mission to defeat Islamic State, U.S. officials said, after President Trump and Syrian President Ahmed al-Sharaa met at the White House on Monday. The move ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...